Author

J. C. Harrell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Hu· 2 shared M. A. Alzubi· 2 shared M. G. Dozmorov· 2 shared M. Puchalapalli· 2 shared M. Shende· 2 shared T. H. Turner· 2 shared A. C. Faber· 1 shared A. K. Yu· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Hu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Genomic screening reveals UBA1 as a potent and druggable target in c-MYC-high TNBC models

S. Jacob, T. H. Turner, J. Cai, K. V. Floros, A. K. Yu, C. M. Coon, R. Khatri, M. A. Alzubi, C. T. Jakubik, Y. M. Bouck, M. Puchalapalli, M. Shende, M. G. Dozmorov, S. Boikos, B. Hu, , A. C. Faber

The paper identifies UBA1 as a druggable target in c-MYC-high TNBC models, showing TAK-243 induces ER-stress and apoptosis in vitro and in vivo.

bioRxiv · May 17, 2022Cancer Biology

Exploitation of sulfated glycosaminoglycan status for precision medicine of platinums in triple-negative breast cancer

J. D. Hampton, E. J. Peterson, S. J. Katner, T. H. Turner, M. A. Alzubi, J. C. Harrell, M. G. Dozmorov, P. J. Gigliotti, V. Kraskauskiene, M. Shende, M. O. Idowu, M. Puchalapalli, B. Hu, L. Litovchick, E. Katsuta, , J. E. Koblinski

This study identifies sulfated glycosaminoglycan (sGAG) levels as a biomarker predicting response to Triplatin in triple-negative breast cancer (TNBC), showing improved efficacy compared to carboplatin in sGAG-high tumors.

bioRxiv · May 5, 2021Pharmacology & Toxicology